Loading...
EHA congress2021-09-15T08:05:00+01:00

ASCO/EHA/ICML 2021

 

Lecture Board: Othman Al-Sawaf, MD; Stephen M. Ansell, MD; PhD Jorge Castillo, MD; Chan Cheah, MBBS; Jeff Sharman, MD
Medical Writer: Dr. Judith Moser

Preface – ASCO/EHA/ICML 2021

Preface – ASCO/EHA/ICML 2021 Véronique Leblond, MD Department of Hematology, Pitié Salpêtrière Hospital Paris, France Dear Colleagues, As virtual scientific conferences are becoming part of our daily routine as clinicians and researchers, information in individual areas of interest is easily accessible across different congresses.

CLL/SLL: current perspectives across a range of potent agents

CLL/SLL: current perspectives across a range of potent agents ALPINE: zanubrutinib vs. ibrutinib The introduction of effective inhibitors of B-cell receptor signaling such as the BTK inhibitor ibrutinib has transformed the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Extending anti-PD-1–based options in the setting of Hodgkin lymphoma

Extending anti-PD-1–based options in the setting of Hodgkin lymphoma Patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) have poor prognosis, which also applies to those with chemotherapy-resistant disease who are ineligible for HDT/ASCT [1-4].

Novel bispecific antibodies in CD20-positive B-cell non-Hodgkin lymphomas

Novel bispecific antibodies in CD20-positive B-cell non-Hodgkin lymphomas Glofitamab step-up dosing The T-cell–engaging bispecific antibody glofitamab has been designed with a 2:1 configuration that enables bivalent binding to CD20 on B cells and monovalent binding to CD3 on T cells [1]. Compared to alternative bispecific formats, this offers greater avidity, potency and combinability with other anti-CD20 IgG antibodies.

Downloads

All downloads from ASCO/EHA/ICML 2021

EHA ppt 2021

Slide Kit B-cell

EHA 2021 Download

Full report (english)

EXPERT VIDEOS

All videointerviews from ASCO/EHA/ICML 2021

Alvaro Alencar discusses which first-line treatment options might soon be established for newly diagnosed patients with mantle cell lymphoma who are not eligible for intensive therapy, what can be expected in terms of innovative approaches in the setting of R/R mantle cell lymphoma or marginal zone lymphoma and highlights the need for robust prognostic tools allowing stratification of treatment modalities.

Matthew Davids depicts the most interesting trial results in the field of CLL treatment at the EHA 2021 congress, gives an outlook on the most promising agents currently tested for use not only in elderly but also in young, fit CLL patients and talks about combinations that might be implemented as pillars of CLL treatment based on current trials.

Wojciech Jurczak gives an overview of the advantages of new BTK inhibitors, the results of the ALPINE trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory CLL/SLL and talks about which new developments can be expected in the field of innovative BTK inhibitors in the treatment of CLL and other indications.

Carol Moreno highlights the CLL study results from EHA and ICML, enlarges on fixed-duration regimens in CLL treatment, the importance of long-term follow-up findings obtained in important trials such as CLL14 and ELEVATE-TN as well as data from the ALPINE and ELEVATE-RR studies and shares her thoughts on the role of new agents such as zanubrutinib in the overall treatment landscape.

Anthony Mato talks about the study highlights presented at EHA and ICML, innovative treatment approaches currently tested for use in CLL that appear most promising and explains how the prognosis of CLL patients might change due to new therapies in the years to come and summarizes potential strategies to prevent and overcome resistance to targeted therapies.

Christian Buske relates to recent developments with respect to the role of BTK inhibitors and their potential future combination partners in the treatment of patients with Waldenström’s macroglobulinemia, the results of the iNNOVATE study and personalized treatment according to genotypes.

EHA 2020 – virtual

Lecture Board: Othman Al-Sawaf, MD; Shirley D’Sa, MD; Heinz Ludwig, MD; Rory McCulloch, MD; Alexander Röth, MD, PhD; Constantine Tam, MD
Medical Writer: Dr. Judith Moser

Preface – EHA 2020

Preface – EHA 2020 Constantine Tam, MB, BS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne Melbourne, Australia Dear Colleagues, Due to the circumstances brought about by the COVID-19 pandemic, the 25th European Hematology Association (EHA) Annual Congress had to take place as a virtual edition, although this raised new possibilities such as a 10-day program.

Waldenström’s macroglobulinemia: BTK inhibition and other treatments

Waldenström’s macroglobulinemia: BTK inhibition and other treatments Within the group of non-Hodgkin lymphoma, Waldenström’s macroglobulinemia (WM), an indolent B-cell lymphoplasmacytic lymphoma, accounts for approximately 2 % of cases [1]. This disease is deemed incurable and typically involves infiltration of tissues such as bone marrow, lymph nodes and/or spleen with clonal lymphoplasmacytic cells, as well as serum monoclonal paraprotein production.

Optimizing timing, efficacy and tolerability in chronic lymphocytic leukemia

Optimizing timing, efficacy and tolerability in chronic lymphocytic leukemia Acalabrutinib vs. ibrutinib In both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), inhibition of Bruton’s tyrosine kinase (BTK) represents a treatment standard as it has improved clinical outcomes [1]. Compared to the first-generation agent ibrutinib, the second-generation, highly selective BTK inhibitor acalabrutinib shows minimal off-target kinase inhibition [2], thus potentially offering an optimized safety profile.

Changing paradigms in the management of mantle cell lymphoma

Changing paradigms in the management of mantle cell lymphoma Mantle cell lymphoma (MCL) is a rare, heterogenous and generally aggressive subtype of B-cell non-Hodgkin lymphoma that remains incurable in the majority of cases. Median survival in non-trial patients has been estimated at 3 to 5 years [1]. First-line therapy usually consists of chemoimmunotherapy, while both immunochemotherapy and targeted agents are recommended in relapsed disease [2]. However, trials increasingly challenge the role of chemotherapy against the novel agents, especially in the front-line setting.

Targeted approaches in various B-cell malignancies

Targeted approaches in various B-cell malignancies Zanubrutinib plus rituximab BTK inhibitors are active in many B-cell malignancies such as mantle cell lymphoma, CLL and Waldenström’s macro­globulinemia, but also in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). Zanubrutinib is currently being assessed in pivotal phase II and III studies in all of these indications. An ongoing, single-arm, multicenter, phase II study is evaluating zanubrutinib plus rituximab in patients with relapsed/refractory non-germinal center B-cell-like (non-GCB) DLBCL (n = 20), FL (n = 16) and MZL (n = 5).

Cold agglutinin disease: on the road to new insights and potential treatment options

Cold agglutinin disease: on the road to new insights and potential treatment options Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia (AIHA) elicited by cold-sensitive antibodies including cold agglutinins. Ninety percent of cold agglutinins belong to the IgM kappa category and bind to red blood cell surface antigens at temperatures of ≤ 37 °C, thus inducing hemolysis [1-3]. CAD accounts for approximately 25 % of AIHA cases, with an incidence and prevalence of 1 case per million persons per year and 16 cases per million persons, respectively [4, 5].

Patient and disease characteristics in a small CAD cohort

Patient and disease characteristics in a small CAD cohort A retrospective analysis hints at the wide range of cold agglutinin disease (CAD) clinical behavior. Koudouna et al. investigated the characteristics of 8 patients with CAD at the time of diagnosis [1]. Median age was 62 years, and 5 patients were women. Hematologic malignancies constituted 50 % of underlying medical conditions; in 37 %, hepatitis B/C was the associated disease, and in 13 %, autoimmune disorders. The median hemoglobin level at presentation was 8.9 g/dL. Slightly elevated serum CRP and ferritin levels represented common findings.

Downloads

All downloads from EHA 2020

Slide Kit CAD / PNH

Full report (english)

memo_InHaematology_Spezial_EHA 2020_german-Cover

Full report (german)

EHA 2020 French PDF

Full report (french)

EXPERT VIDEOS

All videointerviews from EHA 2020

Shirley D’Sa talks about promising new agents/regimens in the treatment of Waldenström’s macroglobulinemia with respect to efficacy and safety, next-generation BTK inhibitors and recent developments in the management of cold agglutinin disease.

Constantine Tam depicts the most interesting trial results in the field of CLL treatment at the EHA congress and gives an outlook on future treatment options for CLL and mantle cell lymphoma.

Veronique Leblond highlights relevant factors for the selection of treatment in newly diagnosed and relapsed Waldenström’s macroglobulinemia, the connection of BTK inhibitors and MYD88 or CXCR4 mutations and discusses the risk-benefit profile of these drugs.

Peter Hillmen gives an overview of the most relevant treatment strategies in ­patients with paroxysmal nocturnal hemoglobinuria and further explains the advantages of proximal over terminal complement inhibition.